Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib in TKI naïve, Advanced ROS1-Positive Non-Small Cell Lung Cancer Patients With Brain Metastases

NCT07083687 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT07083687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07083687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib in TKI naïve, Advanced ROS1-Positive Non-Small Cell Lung Cancer Patients With Brain Metastases
Lead sponsor
Hunan Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 15, 2025
Completion date
December 1, 2028
Enrollment
21 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc)